Background
Chimeric Antigen Receptor (CAR) technology holds considerable promise for advancing HIV-1 cure strategies. However, the elimination of all latently infected cells by targeting gp120 at the cell surface requires complete latency reversal, which remains an unresolved challenge. To bypass this limitation, we have engineered CAR-T cells directed against CD4, the primary HIV receptor, to proof the feasibility of using CAR-T cell technology to eliminate cells harbouring the viral reservoir.
Methods
Second-generation CAR construct (CAR-4) plasmid was generated using a de-novo designed anti-CD4 single-chain variable fragment (scFv) and compared to the anti-CD4 antibody ibalizumab scFv (CAR-Hu5a8) or a non scFv control (Mock). CD8+ T cells transduced with these constructs were co-cultured at different effector-to-target (E:T) ratios and time points with: 1) Kasumi-1 and SUPT-1 cell lines; 2) autologous CD4+ T cells from healthy donors (HD); 3) in vitro HIV-1- infected autologous CD4+ T cells from HD; and 4) autologous CD4+ T cells from 8 people with HIV (PWH) on antiretroviral treatment (ART). We used the humanized FLT-3 murine model (n=6, JAX) to assess the in vivo efficacy of CAR-4 T cells. Cytotoxicity was measured by flow cytometry and cytokines were quantified by Meso Scale Discovery technology.
Results
CAR-4 T cells efficiently eliminated 95–98% of CD4+ cell lines after 48h at a 1:1 E:T ratio. In HD, CAR-4 T cells consistently lysed autologous CD4+ T cells (99.2±0.4%). In co-cultures with in vitro HIV-1-infected HD CD4+ T cells, CAR-4 T cells displayed comparable cytotoxic activity at 48h (97.3±0.5%) although reduced levels of IFNγ, TNFα and Granzyme-A were detected in the supernatants of 24h co-cultures of HIV-infected vs uninfected CD4+ T cells. CAR-4 T cells demonstrated greater cytotoxic capacity than CAR-Hu5a8 T cells. In the humanized murine model, infusion of CAR-4 T cells into uninfected mice resulted in an 89.9±7.4% reduction of hCD4+ T cells at week 3 post-infusion. Finally, ex vivo engineered CAR-4 T cells from PWH eliminated autologous CD4+ T cells after 48h at a 1:1 E:T ratio, with attenuated efficacy compared to HD-derived CAR-4 T cells (50.9±13.9%) but superior to CAR-Hu5a8 T cells (39.9±9.7%).
Conclusions
We designed anti-CD4 CAR-T cells with high capacity in eliminating autologous CD4+ T cells from HD both in vitro and murine models. However, this effect was lessened ex vivo in cells derived from PWH supporting further investigation for the clinical use of CAR-T cells.